Adavosertib
Based on 67 publication(s) in Google Scholar
Adavosertib (AZD-1775; MK-1775) is a potent Wee1 inhibitor with an IC50 of 5.2 nM.
For research use only. We do not sell to patients.
- Purity: 99.96%
- CAS No.: 955365-80-7
- Formula: C27H32N8O2
- Molecular Weight:500.60
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
Publications Citing Use of MedChemExpress (MCE) Adavosertib
More- Signal Transduct Target Ther. 2026 Jan 10;11(1):13. [Abstract]
- Cancer Cell. 2023 Jan 9;41(1):139-163.e17. [Abstract]
- Cell. 2024 Oct 17;187(21):6055-6070.e22. [Abstract]
- J Hematol Oncol. 2018 Aug 1;11(1):99. [Abstract]
- Cancer Res. 2017 Sep 1;77(17):4663-4672. [Abstract]
- Nat Commun. 2026 Feb 12;17(1):1214. [Abstract]
- Nat Commun. 2024 May 7;15(1):3793. [Abstract]
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. [Abstract]
- Leukemia. 2023 Jun;37(6):1336-1348. [Abstract]
- Sci Adv. 2026 Jun 26;12(26):eadz3351. [Abstract]
- Sci Adv. 2021 Apr 30;7(18):eabd4676. [Abstract]
- Blood Cancer J. 2021 Jul 31;11(7):137. [Abstract]
- Cell Rep Med. 2024 May 15:101578. [Abstract]
- Clin Cancer Res. 2020 Jul 1;26(13):3431-3442. [Abstract]
- Cancer Lett. 2026 Feb 4;642:218300.
- Cancer Lett. 2026 Apr 1:642:218300. [Abstract]
- Sci China Life Sci. 2025 Jan;68(1):204-218. [Abstract]
- EMBO J. 2025 Aug;44(15):4378-4405. [Abstract]
- NPJ Precis Oncol. 2025 Jul 1;9(1):209. [Abstract]
- Knowl Based Syst. 2026 Mar 5.
- J Transl Med. 2026 Feb 4;24(1):385. [Abstract]
- Biomed Pharmacother. 2023 Oct:166:115389. [Abstract]
- Oncogene. 2026 Jun 10. [Abstract]
- Oncogene. 2021 Jan;40(3):564-577. [Abstract]
- Blood Adv. 2025 Dec 22:bloodadvances.2025016765. [Abstract]
- Neurotherapeutics. 2025 Apr;22(3):e00575. [Abstract]
- Cell Rep. 2020 Jul 7;32(1):107858. [Abstract]
- Br J Cancer. 2024 Jul;131(2):231-242. [Abstract]
- Int J Mol Sci. 2023 Sep 27;24(19):14646. [Abstract]
- Int J Mol Sci. 2022 Aug 26;23(17):9675. [Abstract]
- Int J Oncol. 2022 May;60(5):54. [Abstract]
- Int J Mol Sci. 2021 Apr 1;22(7):3664. [Abstract]
- Int J Cancer. 2025 Jan 15;156(2):417-430. [Abstract]
- Reprod Biol Endocrinol. 2021 Oct 22;19(1):161. [Abstract]
- Mol Cancer Res. 2020 Jan;18(1):91-104. [Abstract]
- Cell Rep Methods. 2023 Feb 21;3(2):100411. [Abstract]
- Cancers (Basel). 2022 Nov 28;14(23):5854. [Abstract]
- Cancers (Basel). 2021 Aug 20;13(16):4200. [Abstract]
- Cancers. 2019 Oct 25;11(11):1654. [Abstract]
- Cancer Sci. 2023 Dec;114(12):4664-4676. [Abstract]
- Oncol Res. 2025 Oct 22;33(11):3429-3446. [Abstract]
- Neurooncol Adv. 2024 Nov 19;6(1):vdae187. [Abstract]
- Sci Rep. 2021 Feb 4;11(1):3176. [Abstract]
- Sci Rep. 2019 Apr 23;9(1):6458. [Abstract]
- Cell Signal. 2025 Jul:131:111709. [Abstract]
- PLoS One. 2019 Jan 10;14(1):e0209224. [Abstract]
- Tissue Cell. 2025 Aug 18:97:103093. [Abstract]
- Oncologie. 2023 Aug 8.
- bioRxiv. 2026 Mar 13.
- University of North Carolina at Chapel Hill. 2025.
- medRxiv. 2025 Jun 9:2025.06.03.25328936. [Abstract]
- bioRxiv. 2025 May 11.
- bioRxiv. 2025 May 29:2025.05.28.656693. [Abstract]
- bioRxiv. 2025 April 17.
- bioRxiv. 2025 Jan 9:2025.01.09.632184. [Abstract]
- Research Square Preprint. 2024 Nov 06.
- bioRxiv. 2024 Nov 6:2024.11.04.621884. [Abstract]
- Res Sq. 2024 Jun 13.
- Clemson University. 2023 May.
- University of Gothenburg. 2023 Jun 27.
- bioRxiv. 2023 May 18:2023.05.15.540841. [Abstract]
- bioRxiv. January 12, 2022.
- Universitätsklinikum Ulm. 2020 Nov.
- Master of Science in Engineering-Biotechnology. 2020 Jul.
- Georg-August-Universität Göttingen. 2019 Apr.
- University of Bologna. 2016 Apr 22.
- University of Bologna. 2016 Apr.
-
WB
-
WB
-
WB
Biological Activity
IC50: 5.2 nM (Wee1)
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-427 | IC50 |
158 nM
Compound: 1; AZD1775
|
Antiproliferative activity against human A-427 cells assessed as cell growth inhibition measured after 7 days by alamar blue assay
Antiproliferative activity against human A-427 cells assessed as cell growth inhibition measured after 7 days by alamar blue assay
|
[PMID: 37197456] |
| A-427 | IC50 |
311 nM
Compound: AZD1775
|
Antiproliferative activity against human A-427 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human A-427 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 38847373] |
| A-427 | IC50 |
78 nM
Compound: AZD1775
|
Antiproliferative activity against human A-427 cells assessed as reduction in cell viability after 3 days by CellTiter-Glo assay
Antiproliferative activity against human A-427 cells assessed as reduction in cell viability after 3 days by CellTiter-Glo assay
|
[PMID: 34423975] |
| A498 | IC50 |
215.5 nM
Compound: AZD1775
|
Antiproliferative activity against human A498 cells assessed as cell growth inhibition measured after 72 hrs by SRB Assay
Antiproliferative activity against human A498 cells assessed as cell growth inhibition measured after 72 hrs by SRB Assay
|
[PMID: 36170799] |
| BT-549 | IC50 |
0.49 μM
Compound: 1; AZD1775
|
Antiproliferative activity against human BT-549 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay
Antiproliferative activity against human BT-549 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay
|
[PMID: 35231578] |
| Daoy | IC50 |
150 nM
Compound: Adavosertib
|
Antiproliferative activity against human Daoy cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay
Antiproliferative activity against human Daoy cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay
|
[PMID: 33636537] |
| HEK-293T | IC50 |
0.29 μM
Compound: MK-1775
|
Antiproliferative activity against HEK293T cells measured after 72 hrs by CellTiter-Blue assay
Antiproliferative activity against HEK293T cells measured after 72 hrs by CellTiter-Blue assay
|
[PMID: 28792760] |
| LNCaP | IC50 |
0.5 μM
Compound: 1; AZD1775
|
Antiproliferative activity against human LNCaP cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay
Antiproliferative activity against human LNCaP cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay
|
[PMID: 35231578] |
| LoVo | IC50 |
328 nM
Compound: AZD1775
|
Antiproliferative activity against human LoVo cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 method
Antiproliferative activity against human LoVo cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 method
|
[PMID: 38847373] |
| MCF7 | IC50 |
1.1 μM
Compound: 1; AZD1775
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay
|
[PMID: 35231578] |
| MDA-MB-231 | IC50 |
0.26 μM
Compound: MK-1775
|
Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by CellTiter-Blue assay
Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by CellTiter-Blue assay
|
[PMID: 28792760] |
| MM1.S | IC50 |
0.31 μM
Compound: MK-1775
|
Antiproliferative activity against human MM1S cells measured after 72 hrs by CellTiter-Blue assay
Antiproliferative activity against human MM1S cells measured after 72 hrs by CellTiter-Blue assay
|
[PMID: 28792760] |
| MOLT-4 | IC50 |
800 nM
Compound: AZD1775
|
Antiproliferative activity against human MOLT-4 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo Luminescent assay
Antiproliferative activity against human MOLT-4 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo Luminescent assay
|
[PMID: 38663873] |
| Multiple myeloma cancer stem cell | IC50 |
310 nM
Compound: 17
|
Cytotoxicity against human Myeloma-stem like cells
Cytotoxicity against human Myeloma-stem like cells
|
[PMID: 34974338] |
| MV4-11 | IC50 |
132.6 nM
Compound: AZD1775
|
Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition measured after 72 hrs by SRB Assay
Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition measured after 72 hrs by SRB Assay
|
[PMID: 36170799] |
| MV4-11 | IC50 |
95 nM
Compound: AZD1775
|
Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by Celltiter-glo assay
Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by Celltiter-glo assay
|
[PMID: 37167712] |
| NCI-H1299 | IC50 |
0.2837 nM
Compound: AZD-1775; MK-1775
|
Inhibition of cell proliferation in human NCI-H1299 cells incubated for 3 days by MTT assay
Inhibition of cell proliferation in human NCI-H1299 cells incubated for 3 days by MTT assay
|
[PMID: 35051747] |
| NCI-H1299 | IC50 |
104 nM
Compound: AZD1775
|
Antiproliferative activity against human NCI-H1299 cells assessed as cell growth inhibition incubated for 3 days by CellTiter-Glo Luminescent assay
Antiproliferative activity against human NCI-H1299 cells assessed as cell growth inhibition incubated for 3 days by CellTiter-Glo Luminescent assay
|
[PMID: 36075370] |
| NCI-H23 | IC50 |
122 nM
Compound: AZD1775
|
Antiproliferative activity against human NCI-H23 cells assessed as reduction in cell viability after 4 days by CellTiter-Glo assay
Antiproliferative activity against human NCI-H23 cells assessed as reduction in cell viability after 4 days by CellTiter-Glo assay
|
[PMID: 34423975] |
| NCI-H23 | IC50 |
175 nM
Compound: 1; AZD1775
|
Antiproliferative activity against human NCI-H23 cells assessed as cell growth inhibition measured after 7 days by alamar blue assay
Antiproliferative activity against human NCI-H23 cells assessed as cell growth inhibition measured after 7 days by alamar blue assay
|
[PMID: 37197456] |
| PC-3 | IC50 |
8 μM
Compound: 1; AZD1775
|
Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay
Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay
|
[PMID: 35231578] |
| SUM149PT | IC50 |
536.2 nM
Compound: AZD1775
|
Antiproliferative activity against human SUM149PT cells assessed as cell growth inhibition measured after 72 hrs by SRB Assay
Antiproliferative activity against human SUM149PT cells assessed as cell growth inhibition measured after 72 hrs by SRB Assay
|
[PMID: 36170799] |
| T47D | IC50 |
12780 nM
Compound: AZD1775
|
Antiproliferative activity against human T47D cells incubated for 72 hrs by Celltiter-glo assay
Antiproliferative activity against human T47D cells incubated for 72 hrs by Celltiter-glo assay
|
[PMID: 37167712] |
Adavosertib (MK-1775) enhances the cytotoxic effects of 5-FU in p53-deficient human colon cancer cells. Adavosertib (MK-1775) inhibits CDC2 Y15 phosphorylation in cells, abrogates DNA damaged checkpoints induced by 5-FU treatment, and causes premature entry of mitosis determined by induction of Histone H3 phosphorylation[1].
Adavosertib (MK-1775) abrogates the radiation-induced G2 block in p53-defective cells but not in p53 wild-type lines[2].
The combination of NSC 613327 with Adavosertib (MK-1775) produces robust anti-tumor activity and remarkably enhances tumor regression response (4.01 fold) compared to NSC 613327 treatment in p53-deficient tumors[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Adavosertib (MK-1775) (60 mg/kg twice daily, p.o.) enhances H1299 xenograft tumor response to fractionated radiotherapy[2].
Adavosertib (MK-1775) (30 mg/kg. p.o.) regresses tumor growth in PANC198, PANC215 and PANC185 as compared to GEM treated mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 955365-80-7
-
Appearance Solid
-
Molecular Weight 500.60
-
Formula C27H32N8O2
-
Color Light yellow to yellow
-
SMILES
O=C1N(N(C2=NC(NC3=CC=C(C=C3)N4CCN(CC4)C)=NC=C21)C5=NC(C(O)(C)C)=CC=C5)CC=C
-
Synonyms
AZD1775; MK-1775
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (67)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
LncRNA Wee1-AS coordinates oxidative fatty acid metabolism through the activation of mitochondrial CDK1/CYCLIN B1. [Abstract]2026 Jan 10;11(1):13. PMID: 41519884 -
Cancer Cell
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness. [Abstract]2023 Jan 9;41(1):139-163.e17. PMID: 36563681 -
Cell
The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistance. [Abstract]2024 Oct 17;187(21):6055-6070.e22. PMID: 39181133 -
J Hematol Oncol
2018 Aug 1;11(1):99. PMID: 30068368
Adavosertib purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2018 Aug 1;11(1):99. [Abstract]
Representative immunoblots showing the expression of key proteins of the WEE1 pathway after treatment with AZD-1775 (IC50 for each cell line) for 24 h of the indicated cells lines. β-actin is used for loading normalization.
-
Cancer Res
WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer. [Abstract]2017 Sep 1;77(17):4663-4672. PMID: 28652249
Adavosertib purchased from MedChemExpress. Usage Cited in: Cancer Res. 2017 Sep 1;77(17):4663-4672. [Abstract]
Isogenic A549 or H2030 cells expressing full-length LKB1 or kinase-dead LKB1(KDLKB1) are treated with 1 μM AZD1775 or vehicle (DMSO) for 24 hours. Protein lysates are immunoblotted with the indicated antibodies. Actin was used as a loading control.
-
Nat Commun
Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]2026 Feb 12;17(1):1214. PMID: 41680175 -
Nat Commun
An interphase actin wave promotes mitochondrial content mixing and organelle homeostasis. [Abstract]2024 May 7;15(1):3793. PMID: 38714822 -
Sci Transl Med
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]2018 Jul 18;10(450):eaaq1093. PMID: 30021885 -
Leukemia
Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. [Abstract]2023 Jun;37(6):1336-1348. PMID: 36977823 -
Sci Adv
Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities. [Abstract]2026 Jun 26;12(26):eadz3351. PMID: 42361179 -
Sci Adv
2021 Apr 30;7(18):eabd4676. PMID: 33931443 -
Blood Cancer J
High-throughput drug screening identifies the ATR-CHK1 pathway as a therapeutic vulnerability of CALR mutated hematopoietic cells. [Abstract]2021 Jul 31;11(7):137. PMID: 34333533 -
Cell Rep Med
Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations. [Abstract]2024 May 15:101578. PMID: 38776912 -
Clin Cancer Res
Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy. [Abstract]2020 Jul 1;26(13):3431-3442. PMID: 32209571 -
-
Cancer Lett
2026 Apr 1:642:218300. PMID: 41651400 -
Sci China Life Sci
2025 Jan;68(1):204-218. PMID: 39245684 -
EMBO J
2025 Aug;44(15):4378-4405. PMID: 40551011 -
NPJ Precis Oncol
Dual treatment with Val-083 and AZD1775 shows potent anti-tumor activity in diffuse midline glioma models. [Abstract]2025 Jul 1;9(1):209. PMID: 40594881 -
-
J Transl Med
Personalized medicine strategy for MPNSTs: using precision oncology on PDOX models to inform tumor boards. [Abstract]2026 Feb 4;24(1):385. PMID: 41639724 -
Biomed Pharmacother
Wee1 inhibition by MK1775 potentiates gemcitabine through accumulated replication stress leading to apoptosis in biliary tract cancer. [Abstract]2023 Oct:166:115389. PMID: 37659202 -
Oncogene
DNA replication stress and translational repression converge to drive CDK1- and caspase-dependent apoptosis in Ewing sarcoma. [Abstract]2026 Jun 10. PMID: 42270776 -
Oncogene
The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors. [Abstract]2021 Jan;40(3):564-577. PMID: 33191406 -
Blood Adv
Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma. [Abstract]2025 Dec 22:bloodadvances.2025016765. PMID: 41428986 -
Neurotherapeutics
Transcriptionally distinct malignant neuroblastoma populations show selective response to adavosertib treatment. [Abstract]2025 Apr;22(3):e00575. PMID: 40118716 -
Cell Rep
Cyclin N-Terminal Domain-Containing-1 Coordinates Meiotic Crossover Formation with Cell-Cycle Progression in a Cyclin-Independent Manner. [Abstract]2020 Jul 7;32(1):107858. PMID: 32640224 -
Br J Cancer
PARP inhibition leads to synthetic lethality with key splicing-factor mutations in myelodysplastic syndromes. [Abstract]2024 Jul;131(2):231-242. PMID: 38806724 -
Int J Mol Sci
Bortezomib Is Effective in the Treatment of T Lymphoblastic Leukaemia by Inducing DNA Damage, WEE1 Downregulation, and Mitotic Catastrophe. [Abstract]2023 Sep 27;24(19):14646. PMID: 37834095 -
Int J Mol Sci
Compound C Inhibits Renca Renal Epithelial Carcinoma Growth in Syngeneic Mouse Models by Blocking Cell Cycle Progression, Adhesion and Invasion. [Abstract]2022 Aug 26;23(17):9675. PMID: 36077072 -
Int J Oncol
Ricolinostat enhances adavosertib‑induced mitotic catastrophe in TP53‑mutated head and neck squamous cell carcinoma cells. [Abstract]2022 May;60(5):54. PMID: 35348191 -
Int J Mol Sci
Heterogeneities in Cell Cycle Checkpoint Activation Following Doxorubicin Treatment Reveal Targetable Vulnerabilities in TP53 Mutated Ultra High-Risk Neuroblastoma Cell Lines. [Abstract]2021 Apr 1;22(7):3664. PMID: 33915913 -
Int J Cancer
Enhanced pharmacological activities of AKR1C3-activated prodrug AST-3424 in cancer cells with defective DNA repair. [Abstract]2025 Jan 15;156(2):417-430. PMID: 39243400 -
Reprod Biol Endocrinol
2021 Oct 22;19(1):161. PMID: 34686198 -
Mol Cancer Res
Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2. [Abstract]2020 Jan;18(1):91-104. PMID: 31649026 -
Cell Rep Methods
2023 Feb 21;3(2):100411. PMID: 36936075 -
Cancers (Basel)
Drug Repurposing Applications to Overcome Male Predominance via Targeting G2/M Checkpoint in Human Esophageal Squamous Cell Carcinoma. [Abstract]2022 Nov 28;14(23):5854. PMID: 36497337 -
Cancers (Basel)
Novel Insights into the Molecular Regulation of Ribonucleotide Reductase in Adrenocortical Carcinoma Treatment. [Abstract]2021 Aug 20;13(16):4200. PMID: 34439352 -
Cancers
2019 Oct 25;11(11):1654. PMID: 31717700 -
Cancer Sci
Combination therapy with WEE1 inhibition and trifluridine/tipiracil against esophageal squamous cell carcinoma. [Abstract]2023 Dec;114(12):4664-4676. PMID: 37724648 -
Oncol Res
Efficacy of Wee1 G2 Checkpoint Kinase and Mouse Double Minute 2 Homolog Inhibitors in Gastrointestinal Stromal Tumors Determined by p53 Status. [Abstract]2025 Oct 22;33(11):3429-3446. PMID: 41179301 -
Neurooncol Adv
Ion channel modulator DPI-201-106 significantly enhances antitumor activity of DNA damage response inhibitors in glioblastoma. [Abstract]2024 Nov 19;6(1):vdae187. PMID: 39659830 -
Sci Rep
The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers. [Abstract]2021 Feb 4;11(1):3176. PMID: 33542435 -
Sci Rep
Characterization of Three Novel H3F3A-mutated Giant Cell Tumor Cell Lines and Targeting of Their Wee1 Pathway. [Abstract]2019 Apr 23;9(1):6458. PMID: 31015476 -
Cell Signal
2025 Jul:131:111709. PMID: 40037423 -
PLoS One
2019 Jan 10;14(1):e0209224. PMID: 30629587 -
Tissue Cell
Combined inhibition of WEE1 by AZD1775 synergistically enhances CX-5461 mediated DNA damage and induces cytotoxicity in glioblastoma. [Abstract]2025 Aug 18:97:103093. PMID: 40839955 -
-
-
-
medRxiv
Matrix Stiffness Influences Drug Resistance to Gemcitabine Analog and AZD 1775 Combination in PDAC Organoids. [Abstract]2025 Jun 9:2025.06.03.25328936. PMID: 40585160 -
-
bioRxiv
AURKA inhibition amplifies DNA replication stress to foster WEE1 kinase dependency and synergistic antitumor effects with WEE1 inhibition in cancers. [Abstract]2025 May 29:2025.05.28.656693. PMID: 40501675 -
-
bioRxiv
The RING Finger E3 Ligase RNF25 Protects DNA Replication Forks Independently of its Canonical Roles in Ubiquitin Signaling. [Abstract]2025 Jan 9:2025.01.09.632184. PMID: 39829812 -
-
bioRxiv
PAIRWISE: Deep Learning-based Prediction of Effective Personalized Drug Combinations in Cancer. [Abstract]2024 Nov 6:2024.11.04.621884. PMID: 39574568 -
-
-
-
bioRxiv
2023 May 18:2023.05.15.540841. PMID: 37292855 -
-
-
-
-
-
Adavosertib purchased from MedChemExpress. Usage Cited in: University of Bologna. 2016 Apr.
In the blots B-/T-ALL cell lines are incubated for 24 hours with MK-1775 (IC50 value). The homogeneity of the protein loaded (40 μg) is determined using an internal control (β-actin).
Solvent & Solubility
DMSO : 100 mg/mL (199.76 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (4.16 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 0.5% Methylcellulose/saline water
Solubility: 5 mg/mL (9.99 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Total protein is extracted from the cell pellet using a lysis solution containing 50 mM HEPES (pH 7.9), 0.4 mol/L NaCl, and 1 mM EDTA and fortified with 10 µL/mL phosphatase inhibitor cocktail 1, 10 µL/mL phosphatase inhibitor cocktail 2, 10 µL/mL protease inhibitor, and 1% NP-40. Protein concentration of the lysates is determined by the Bio-Rad protein assay. Equal amounts of protein are separated by 12% SDS-PAGE and transferred to an Immobilon membrane. Nonspecific binding sites on the membrane are blocked in 5% nonfat dry milk in Tris (20 mM)-buffered saline (150 mM, pH 7.4) with 0.1% Tween (TBS-T). Protein signals are detected by incubating the membrane in primary antibody in 5% nonfat dry milk overnight at 4°C, followed by a 45-min incubation in the appropriate peroxidase-conjugated secondary antibody. The membrane is then developed by enhanced chemiluminescence with ECL plus Western Blotting Detection Reagents on a Typhoon 9400 scanner.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Tumor xenografts are produced in the leg by im inoculation of 1×106 Calu-6 cells in 10 µL. Irradiation and Adavosertib (MK-1775) treatment are started when tumors reach 8 mm diameter and continue for 5 days. Gamma-rays are delivered locally to the tumor-bearing legs of unanesthetized mice using a small-animal irradiator consisting of two parallel-opposed 137Cs sources, at a dose rate of 5 Gy/min. Tumors are irradiated twice daily separated by 6 h. Adavosertib (MK-1775) is given by gavage in 0.1 mL volumes 1 h before and 2 h after the first daily radiation dose.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Hirai H, et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-FU. Cancer Biol Ther. 2010 Apr;9(7):514-22. [Content Brief]
[2]. Bridges KA, et al. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res. 2011 Sep 1;17(17):5638-48. Epub 2011 Jul 28. [Content Brief]
[3]. Rajeshkumar NV, et al. MK-1775, a potent Wee1 inhibitor, synergizes with NSC 613327 to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.Clin Cancer Res. 2011 May 1;17(9):2799-806. Epub 2011 Mar 9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9976 mL | 9.9880 mL | 19.9760 mL | 49.9401 mL |
| 5 mM | 0.3995 mL | 1.9976 mL | 3.9952 mL | 9.9880 mL | |
| 10 mM | 0.1998 mL | 0.9988 mL | 1.9976 mL | 4.9940 mL | |
| 15 mM | 0.1332 mL | 0.6659 mL | 1.3317 mL | 3.3293 mL | |
| 20 mM | 0.0999 mL | 0.4994 mL | 0.9988 mL | 2.4970 mL | |
| 25 mM | 0.0799 mL | 0.3995 mL | 0.7990 mL | 1.9976 mL | |
| 30 mM | 0.0666 mL | 0.3329 mL | 0.6659 mL | 1.6647 mL | |
| 40 mM | 0.0499 mL | 0.2497 mL | 0.4994 mL | 1.2485 mL | |
| 50 mM | 0.0400 mL | 0.1998 mL | 0.3995 mL | 0.9988 mL | |
| 60 mM | 0.0333 mL | 0.1665 mL | 0.3329 mL | 0.8323 mL | |
| 80 mM | 0.0250 mL | 0.1249 mL | 0.2497 mL | 0.6243 mL | |
| 100 mM | 0.0200 mL | 0.0999 mL | 0.1998 mL | 0.4994 mL |